Injective's INJ rises as much as 28% in a day as staked ETF filings draw focus
In brief
- INJ rose 23% to 28% in 24 hours on October 16, per Crypto Briefing.
- INJ topped $9.10 intraday, pulling ahead of layer-1 peers NEAR, Sei and Cosmos Hub.
- Crypto Briefing named 21Shares' amended Injective ETF filing as the likely catalyst.
- Canary Capital and REX-Osprey have advanced their own staked INJ ETF filings.
- Regulators have not approved any of the proposed INJ ETF products.
What moved INJ
Crypto Briefing reported that trading volume rose above normal levels during the move. It didn't tie the rally to a single confirmed cause. It did name a likely one, though: 21Shares.
Around September 18, 2026, 21Shares amended its filing for an Injective ETF. The proposed product would hold INJ directly (rather than tracking it through derivatives), would allow discretionary staking and is aiming for a Nasdaq listing under the ticker TINJ. It remains a proposal awaiting regulatory review and hasn't been approved.
Staked ETF filings pile up
21Shares isn't the only one. Canary Capital and REX-Osprey have advanced their own filings for staked INJ ETFs, and Crypto Briefing said those structures could potentially stake 90% of their holdings.
All three are still proposals waiting on regulators.
If regulators do approve a staked INJ ETF, the outlet said, the 21Shares, Canary Capital and REX-Osprey products could give the token to investors who don't use crypto exchanges. It also argued that a fund staking up to 90% of its holdings, together with supply contraction from IIP-617, could further tighten available INJ supply.
Supply mechanics and the 30-day run
The one-day jump comes on top of a bigger run. INJ has gained roughly 67% to 70% over the past 30 days, per Crypto Briefing, and much of that gain has been attributed to the token's supply mechanics.
Those mechanics go back to January 2026, when the Injective community passed IIP-617 (a governance proposal that enables ongoing supply contraction for INJ). Crypto Briefing also cited a reported revenue-to-fully diluted valuation ratio of about 0.95 for Injective, which it described as reportedly the highest among layer-1 networks and ahead of Solana and Arbitrum.
Frequently asked questions
What caused INJ's price jump on October 16, 2026?
Crypto Briefing said the most important catalyst appears to be 21Shares, which amended its filing for an Injective ETF around September 18, 2026. The outlet presented this as its own view, not a confirmed cause. Trading volume also rose above normal levels during the move.
Which firms have filed for INJ ETFs?
21Shares has amended its filing for an Injective ETF that would hold INJ directly, allow discretionary staking and list on Nasdaq under the ticker TINJ. Canary Capital and REX-Osprey have advanced their own filings for staked INJ ETFs. All are proposals awaiting regulatory review.
What is IIP-617?
IIP-617 is a governance proposal the Injective community passed in January 2026. It enables ongoing supply contraction for INJ. Crypto Briefing said this, combined with ETFs that could stake up to 90% of their holdings, could further tighten available INJ supply.
